Long-term results from a randomized trial confirmed that early rituximab monotherapy for advanced-stage, asymptomatic, low ...

Researchers have identified a new set of urine-based biomarkers that can accurately detect both the presence and severity of ...

Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, today announced the appointment of Tariq Mughal, MD FRCP FRCPath, as Chief Medic ...

Landmark Science, a premier provider of real-world evidence (RWE) solutions, is redefining industry standards with its white-glove, high-touch approach to evidence generation. With long-standing roots ...

We recently published a list of Top 11 Small Cap Stocks to Buy with Biggest Upside Potential. In this article, we are going ...

In this article, we will look at the Top 11 Small Cap Stocks to Buy with Biggest Upside Potential.

Physician's Weekly has developed an innovative, peer-led initiative designed to transform the way oncologists engage with ...

Regeneron will present new and updated data on its oncology and hematology portfolio at the prestigious 2025 ASCO Annual Meeting, highlighting its commitment to research in difficult-to-treat cancers.

The addition of chemotherapy to radiotherapy was not associated with improved survival among patients with intermediate-risk cervical cancer, according to study results published in JAMA Oncology.

IO Biotech's first-in-class vaccine performs double duty, killing cancer cells and enhancing the tumor microenvironment. A ...

Most patients achieved complete response with dostarlimab alone. Further research is needed given the variability of responses. Neoadjuvant immunotherapy alone resulted in significant treatment ...

SAN DIEGO, May 01, 2025--(BUSINESS WIRE)--Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and part of JSR Life Sciences and Japan-based JSR ...